8-K: Pfizer Reports Solid 2025 Results, Reaffirms 2026 Guidance

Pfizer Inc. announced its fourth-quarter and full-year 2025 financial results, reaffirming its full-year 2026 financial guidance and highlighting strong non-COVID portfolio growth.

Summary

• Full-Year 2025 Revenues totaled $62.6 billion, reflecting a 2% year-over-year operational decline.
• Excluding contributions from Paxlovid and Comirnaty, full-year 2025 revenues grew 6% operationally.
• Fourth-Quarter 2025 Revenues were $17.6 billion, representing a 3% year-over-year operational decline.
• Excluding contributions from Paxlovid and Comirnaty, fourth-quarter 2025 revenues grew 9% operationally.
• Full-Year 2025 Reported Diluted EPS was $1.36, and Adjusted Diluted EPS was $3.22.
• Fourth-Quarter 2025 Reported Diluted Loss Per Share (LPS) was $(0.29), and Adjusted Diluted EPS was $0.66.
• Reaffirmed full-year 2026 financial guidance, including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a range of $2.80 to $3.00.
• Anticipates approximately $5 billion in revenues from COVID-19 products and an expected year-over-year negative revenue impact of approximately $1.5 billion due to product loss of exclusivity (LOE) in 2026.
• Advanced 11 key pivotal study starts in 2025 and plans approximately 20 key pivotal study starts for 2026, including 10 for ultra-long-acting obesity assets acquired from Metsera and 4 for PF-08634404 (a PD-1 x VEGF bispecific antibody in-licensed from 3SBio).
• Invested $10.4 billion in internal research and development projects and approximately $8.8 billion in business development transactions in 2025.
• Returned $9.8 billion to shareholders through cash dividends, or $1.72 per share of common stock, in 2025.
• Reached an agreement in January 2026 to exit its 11.7% investment in ViiV Healthcare Limited for $1.875 billion in cash, with completion expected in Q1 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report. While overall revenues declined due to COVID-19 product normalization and significant impairments occurred, the strong operational growth in the non-COVID portfolio and robust pipeline advancements, particularly in obesity and oncology, provide a solid foundation for future growth and justify the reaffirmed guidance.

Positives

• Non-COVID portfolio delivered strong operational revenue growth of 6% for full-year 2025 and 9% for fourth-quarter 2025.
• Achieved solid financial performance and strengthened the foundation for future growth through excellent execution in 2025.
• Advanced 11 key pivotal study starts in 2025 and plans approximately 20 key pivotal study starts for 2026, indicating a robust pipeline.
• Announced positive Phase 3 results for Braftovi in metastatic colorectal cancer, demonstrating a clinically meaningful and statistically significant improvement in objective response rate (64.4% vs 39.2%).
• Detailed Phase 3 BASIS study results for Hympavzi showed superiority in improving key bleeding outcomes for hemophilia A or B with inhibitors.
• Positive topline results from Phase 3 EV-304 clinical trial for Padcev in combination with pembrolizumab for muscle-invasive bladder cancer, meeting primary endpoint of event-free survival and key secondary endpoint of overall survival.
• U.S. FDA approved Padcev in combination with pembrolizumab for neoadjuvant and adjuvant treatment of adult patients with MIBC in November 2025.
• Detailed Phase 3 HER2CLIMB-05 trial results for Tukysa showed a 35.9% reduction in the risk of disease progression or death in HER2+ metastatic breast cancer.
• Positive topline results from Phase 2b VESPER-3 study for ultra-long-acting GLP-1 (PF3944 / MET-097i) in obesity/overweight, meeting primary endpoint of statistically significant weight reduction with a competitive tolerability profile.
• Cost of Sales as a percentage of revenues decreased by 3.2 percentage points in Q4 2025, driven by a favorable sales mix and lower amortization.
• SI&A Expenses decreased 3% operationally in Q4 2025, reflecting focused investments and ongoing productivity improvements.
• Net interest expense decreased in full-year 2025 due to lower commercial paper outstanding and increased interest income from a higher average investment asset balance.

Negatives

• Total revenues declined 2% operationally for full-year 2025 and 3% operationally for fourth-quarter 2025.
• Significant year-over-year decline in COVID-19 product revenues: Comirnaty down 35% operationally in Q4 2025, and Paxlovid down 70% operationally in Q4 2025.
• Reported Diluted Loss Per Share (LPS) of $(0.29) for the fourth quarter of 2025.
• Incurred total non-cash intangible asset impairment charges of $4.4 billion in Q4 2025, including $1.6 billion for disitamab vedotin, $820 million for Tukysa, $820 million for osivelotor, and approximately $813 million for certain U.S. sterile injectable and hospital products.
• Anticipates a negative revenue impact of approximately $1.5 billion in 2026 due to certain products experiencing loss of exclusivity (LOE).
• Anticipates a higher tax rate on Adjusted income for full-year 2026 compared to full-year 2025.
• Lower net gains on equity securities and the non-recurrence of gains from the partial sale of Haleon plc equity in Q4 2025 compared to Q4 2024.
• Abrysvo experienced lower vaccination rates for the older adult indication in the U.S. following an updated recommendation by the Advisory Committee on Immunization Practices.
• Eliquis sales were partially offset by generic entry and price erosion in certain international markets and lower inventory in the U.S. distribution channel.
• Prevnar family experienced lower market share in the U.S. and timing of shipments in certain international markets.
• Vyndaqel family and Lorbrena faced lower net price in the U.S. due to higher manufacturer discounts resulting from the IRA Medicare Part D Redesign and new payer contracts.

Risks

• The outcome of research and development (R&D) activities, including the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for trials, regulatory submission dates, and/or regulatory approval and/or launch dates.
• The possibility of unfavorable pre-clinical and clinical trial results, including new data and further analyses of existing data, and risks associated with preliminary, early stage or interim data.
• Regulatory decisions impacting labeling, approval or authorization, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, and developments regarding potential product impurities.
• Uncertainties regarding the ability to obtain or maintain, and the scope of, recommendations by technical or advisory committees, and the timing of, and ability to obtain, pricing/reimbursement, approvals and product launches.
• Claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including from post-approval clinical trials, pharmacovigilance or Risk Evaluation and Mitigation Strategies.
• The success and impact of external business development activities, including the ability to identify and execute opportunities, satisfy closing conditions, realize anticipated benefits, and challenges integrating businesses and operations.
• Competition from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates.
• Difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs.
• The impact of public health outbreaks, epidemics or pandemics on business, operations and financial condition and results.
• Risks and uncertainties related to Comirnaty and Paxlovid or any potential future COVID-19 vaccines, treatments or combinations, including reduced demand, excess inventory, and ability to develop variant adapted vaccines.
• Trends toward managed care and healthcare cost containment, and the ability to obtain or maintain timely or adequate pricing or favorable formulary placement for products.
• Interest rate and foreign currency exchange rate fluctuations, including the impact of global trade tensions, currency devaluations and monetary policy actions.
• Any significant issues involving largest wholesale distributors or government customers.
• The impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain.
• Any significant issues related to the outsourcing of certain operational and staff functions to third parties, or issues related to JVs and other third-party business arrangements.
• Uncertainties related to general economic, political, business, industry, regulatory and market conditions, including inflation, interest rate fluctuations, and changes in global financial markets.
• The exposure of global operations to possible capital and exchange controls, economic conditions, expropriation, sanctions, tariffs and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes.
• Risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy regarding tariffs or other trade or foreign policy and/or the impact of any potential U.S. Governmental shutdowns.
• The impact of disruptions related to climate change and natural disasters, and any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action.
• The impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments (e.g., nitrosamines, Oxbryta withdrawal).
• The risk of an impairment charge related to intangible assets, goodwill or equity-method investments.
• The impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives.
• The impact of any U.S. healthcare reform or legislation, including executive orders or other change in laws, regulations or policy, or any significant spending reduction or cost control efforts affecting Medicare, Medicaid, the 340B Drug Pricing Program or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022 (IRA) and the IRA Medicare Part D Redesign.
• Risks and uncertainties related to the impact of Pfizer's voluntary agreement with the U.S. Government designed to lower drug costs for U.S. patients and to include certain Pfizer products on the TrumpRx.gov platform.
• U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing (including international reference pricing), intellectual property, product approval processes, reimbursement or access to medicines and vaccines, tax changes or other restrictions on advertising.
• Legislation or regulatory action and/or policy efforts in markets outside of the U.S., such as China or Europe, including laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, data protection and cybersecurity, reimbursement or access.
• Legal defense costs, insurance expenses, settlement costs and contingencies, including those related to legal proceedings and actual or alleged environmental contamination, and the risk and impact of an adverse decision or settlement.
• Governmental laws, regulations and policies affecting operations, including the IRA, the One Big Beautiful Bill Act, global minimum taxation requirements, government cost-cutting measures, restrictions related to certain data transfers, and potential changes to existing tax laws or tariffs.
• The risk that currently pending or future patent applications may not be granted, or any patent-term extensions sought may not be granted.
• Risks to products, patents and other intellectual property, such as claims of invalidity, patent infringement, or challenges by collaboration/licensing partners.
• Any significant breakdown or interruption of information technology systems and infrastructure (including cloud services).
• Any business disruption, theft of confidential or proprietary information, security threats, extortion or integrity compromise resulting from a cyber-attack, which may include those using adversarial artificial intelligence techniques.
• Risks and challenges related to the use of software, systems and services that include artificial intelligence-based functionality and other emerging technologies.

Future Outlook

Pfizer reaffirmed its full-year 2026 financial guidance, projecting revenues between $59.5 billion and $62.5 billion and Adjusted Diluted EPS between $2.80 and $3.00. This guidance anticipates approximately $5 billion from COVID-19 products and a $1.5 billion negative impact from product loss of exclusivity. The company plans around 20 key pivotal study starts in 2026, focusing on oncology and obesity assets, and expects stable gross and operating margins with an anticipated higher tax rate on Adjusted income versus full-year 2025.

Management Comments

• Dr. Albert Bourla, Chairman and CEO: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, including our expectation for approximately 20 key pivotal study starts, and continued strategic investment to maximize our opportunities for industry-leading growth at the end of the decade."
• David Denton, CFO and EVP: "I'm pleased with our solid financial results in 2025. With focused commercial execution, we delivered full-year operational revenue growth of 6% for our non-COVID portfolio, and our continued financial discipline drove strong EPS performance. Today, we are reaffirming our full-year 2026 financial guidance."

Industry Context

StockSavvy.ai notes that Pfizer's focus on diversifying its revenue streams away from COVID-19 products aligns with a broader pharmaceutical industry trend of strategic pipeline development and M&A to counter patent cliffs and evolving market demands. The significant investment in obesity and oncology assets, including the Metsera acquisition and YaoPharma in-licensing, positions Pfizer to compete in highly lucrative and rapidly expanding therapeutic areas, mirroring similar strategic moves by peers like Eli Lilly and Novo Nordisk in the GLP-1 space. The decline in COVID-19 product sales reflects the transition to an endemic market, a challenge many vaccine and therapeutic developers are navigating.

Comparison to Industry Standards

• Pfizer's 6% operational growth in its non-COVID portfolio for FY2025 is a solid performance, especially when compared to the overall industry average growth which can vary but often hovers in the mid-single digits for established large pharma.
• The aggressive pipeline expansion with ~20 pivotal study starts planned for 2026, particularly in obesity (e.g., ultra-long-acting GLP-1 assets from Metsera), positions Pfizer to potentially challenge market leaders like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, which have seen explosive growth.
• The $4.4 billion intangible asset impairment charge in Q4 2025, including for assets like disitamab vedotin and Tukysa, indicates a re-evaluation of pipeline assets, a common practice in the R&D-intensive pharmaceutical sector, but the magnitude suggests significant shifts in commercial forecasts or development plans for these specific projects.

Legal Proceedings

• The company incurred certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
• Risks include legal defense costs, insurance expenses, settlement costs, and contingencies related to legal proceedings and actual or alleged environmental contamination.
• There is a risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings.
• The company faces the risk and impact of tax-related litigation and investigations.

Stakeholder Impact

• Shareholders: Potential for long-term value enhancement through pipeline growth and strategic investments, but short-term volatility due to revenue declines and impairments. Continued dividends provide direct return.
• Employees: Impact from enterprise-wide cost realignment program, which includes employee termination costs.
• Customers: Continued availability of key products and potential for new treatments from the pipeline, especially in oncology and cardiometabolic diseases.
• Suppliers: Ongoing business relationships, but potential for shifts based on pipeline focus and manufacturing optimization.
• Creditors: Company expects to continue to de-lever over the longer term, indicating a commitment to financial health.

Next Steps

• Approximately 20 key pivotal study starts planned for 2026, including 10 pivotal trials for ultra-long-acting obesity assets acquired from Metsera and 4 pivotal trials for PF-08634404 (a PD-1 x VEGF bispecific antibody in-licensed from 3SBio).
• Detailed results from the Phase 2b VESPER-3 study for PF3944 (MET-097i) will be presented on June 6, 2026, at the 86th Scientific Sessions of the American Diabetes Association.
• The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use and subsequently the European Commission are expected to share their opinion and decision on Padcev in combination with pembrolizumab in 2026.
• Completion of the transaction to exit the 11.7% investment in ViiV Healthcare Limited is expected to occur in the first quarter of 2026.
• The company expects to continue to de-lever over the longer term in a prudent manner.
• The company maintains the potential to resume the return of capital to shareholders through value-enhancing share repurchases in the future, though none are anticipated in 2026.

Key Dates

Recommendation

While Pfizer faces headwinds from declining COVID-19 product sales and significant intangible asset impairments, the strong operational growth in its non-COVID portfolio and a robust, strategically focused late-stage pipeline, particularly in high-growth areas like obesity and oncology, provide a solid foundation. The reaffirmation of 2026 guidance suggests stability. Investors should hold, monitoring pipeline execution and the impact of new product launches against the backdrop of patent expirations and market competition.

Keywords

Pfizer, PFE, Pharmaceuticals, Biopharma, Financial Results, Earnings, 2025 Results, 2026 Guidance, Pipeline, R&D, Oncology, Obesity, GLP-1, Metsera, YaoPharma, Abrysvo, Eliquis, Prevnar, Vyndaqel, Padcev, Comirnaty, Paxlovid, SEC Filing, 8-K